Abstract
Summary
LPI (LP Information)' newest research report, the “Nintedanib Industry Forecast” looks at past sales and reviews total world Nintedanib sales in 2022, providing a comprehensive analysis by region and market sector of projected Nintedanib sales for 2023 through 2029. With Nintedanib sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nintedanib industry.
This Insight Report provides a comprehensive analysis of the global Nintedanib landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nintedanib portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Nintedanib market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nintedanib and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nintedanib.
The global Nintedanib market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Nintedanib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Nintedanib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Nintedanib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Nintedanib players cover Boehringer Ingelheim Pharma. etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Nintedanib market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
100mg*10 Capsules
150mg*10 Capsules
100mg*30 Capsules
150mg*30 Capsules
150mg*60 Capsules
Segmentation by application
Locally Advanced NSCLC
Variant NSCLC
Locally Recurrent NSCLC
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer Ingelheim Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nintedanib market?
What factors are driving Nintedanib market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nintedanib market opportunities vary by end market size?
How does Nintedanib break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
This Insight Report provides a comprehensive analysis of the global Nintedanib landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nintedanib portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Nintedanib market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nintedanib and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nintedanib.
The global Nintedanib market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Nintedanib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Nintedanib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Nintedanib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Nintedanib players cover Boehringer Ingelheim Pharma. etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Nintedanib market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
100mg*10 Capsules
150mg*10 Capsules
100mg*30 Capsules
150mg*30 Capsules
150mg*60 Capsules
Segmentation by application
Locally Advanced NSCLC
Variant NSCLC
Locally Recurrent NSCLC
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer Ingelheim Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nintedanib market?
What factors are driving Nintedanib market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nintedanib market opportunities vary by end market size?
How does Nintedanib break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nintedanib Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Nintedanib by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Nintedanib by Country/Region, 2018, 2022 & 2029
2.2 Nintedanib Segment by Type
2.2.1 100mg*10 Capsules
2.2.2 150mg*10 Capsules
2.2.3 100mg*30 Capsules
2.2.4 150mg*30 Capsules
2.2.5 150mg*60 Capsules
2.3 Nintedanib Sales by Type
2.3.1 Global Nintedanib Sales Market Share by Type (2018-2023)
2.3.2 Global Nintedanib Revenue and Market Share by Type (2018-2023)
2.3.3 Global Nintedanib Sale Price by Type (2018-2023)
2.4 Nintedanib Segment by Application
2.4.1 Locally Advanced NSCLC
2.4.2 Variant NSCLC
2.4.3 Locally Recurrent NSCLC
2.5 Nintedanib Sales by Application
2.5.1 Global Nintedanib Sale Market Share by Application (2018-2023)
2.5.2 Global Nintedanib Revenue and Market Share by Application (2018-2023)
2.5.3 Global Nintedanib Sale Price by Application (2018-2023)
3 Global Nintedanib by Company
3.1 Global Nintedanib Breakdown Data by Company
3.1.1 Global Nintedanib Annual Sales by Company (2018-2023)
3.1.2 Global Nintedanib Sales Market Share by Company (2018-2023)
3.2 Global Nintedanib Annual Revenue by Company (2018-2023)
3.2.1 Global Nintedanib Revenue by Company (2018-2023)
3.2.2 Global Nintedanib Revenue Market Share by Company (2018-2023)
3.3 Global Nintedanib Sale Price by Company
3.4 Key Manufacturers Nintedanib Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nintedanib Product Location Distribution
3.4.2 Players Nintedanib Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Nintedanib by Geographic Region
4.1 World Historic Nintedanib Market Size by Geographic Region (2018-2023)
4.1.1 Global Nintedanib Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Nintedanib Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Nintedanib Market Size by Country/Region (2018-2023)
4.2.1 Global Nintedanib Annual Sales by Country/Region (2018-2023)
4.2.2 Global Nintedanib Annual Revenue by Country/Region (2018-2023)
4.3 Americas Nintedanib Sales Growth
4.4 APAC Nintedanib Sales Growth
4.5 Europe Nintedanib Sales Growth
4.6 Middle East & Africa Nintedanib Sales Growth
5 Americas
5.1 Americas Nintedanib Sales by Country
5.1.1 Americas Nintedanib Sales by Country (2018-2023)
5.1.2 Americas Nintedanib Revenue by Country (2018-2023)
5.2 Americas Nintedanib Sales by Type
5.3 Americas Nintedanib Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nintedanib Sales by Region
6.1.1 APAC Nintedanib Sales by Region (2018-2023)
6.1.2 APAC Nintedanib Revenue by Region (2018-2023)
6.2 APAC Nintedanib Sales by Type
6.3 APAC Nintedanib Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Nintedanib by Country
7.1.1 Europe Nintedanib Sales by Country (2018-2023)
7.1.2 Europe Nintedanib Revenue by Country (2018-2023)
7.2 Europe Nintedanib Sales by Type
7.3 Europe Nintedanib Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nintedanib by Country
8.1.1 Middle East & Africa Nintedanib Sales by Country (2018-2023)
8.1.2 Middle East & Africa Nintedanib Revenue by Country (2018-2023)
8.2 Middle East & Africa Nintedanib Sales by Type
8.3 Middle East & Africa Nintedanib Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nintedanib
10.3 Manufacturing Process Analysis of Nintedanib
10.4 Industry Chain Structure of Nintedanib
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nintedanib Distributors
11.3 Nintedanib Customer
12 World Forecast Review for Nintedanib by Geographic Region
12.1 Global Nintedanib Market Size Forecast by Region
12.1.1 Global Nintedanib Forecast by Region (2024-2029)
12.1.2 Global Nintedanib Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Nintedanib Forecast by Type
12.7 Global Nintedanib Forecast by Application
13 Key Players Analysis
13.1 Boehringer Ingelheim Pharma
13.1.1 Boehringer Ingelheim Pharma Company Information
13.1.2 Boehringer Ingelheim Pharma Nintedanib Product Portfolios and Specifications
13.1.3 Boehringer Ingelheim Pharma Nintedanib Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Boehringer Ingelheim Pharma Main Business Overview
13.1.5 Boehringer Ingelheim Pharma Latest Developments
14 Research Findings and Conclusion